3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Neoplasms
17
Breast Neoplasms
10
Carcinoma, Non-Small-Cell Lung
9
Neoplasm Metastasis
6
Prostatic Neoplasms
5
Melanoma
5
Lung Neoplasms
5
Solid Tumor
3
Pain, Postoperative
3
Lymphoma, Non-Hodgkin
3
Lymphoma
3
Leukemia, Myeloid, Acute
3
Gastrointestinal Stromal Tumors
3
Colorectal Neoplasms
3
Anxiety Disorders
3
Recurrence
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pancreatic Neoplasms
2
Pain
2
Glioma
2
Colonic Neoplasms
2
Choledocholithiasis
2
Choledochal Cyst
2
Carcinoma
2
Advanced Solid Tumor
2
Advanced Malignancies
2
cMET-dysregulated Advanced Solid Tumors
1
Urothelial Cancer
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Interventions
Doxorubicin
141
Ifosfamide
85
Radiotherapy
80
Cyclophosphamide
72
Gemcitabine
63
Filgrastim
54
pembrolizumab
43
pazopanib
39
Etoposide
39
Docetaxel
39
Vincristine
37
Cisplatin
35
Trabectedin
32
Nivolumab
32
Irinotecan
26
Magnetic Resonance Spectroscopy
25
Carboplatin
25
Temozolomide
23
Ipilimumab
22
Bevacizumab
20
Radiation
19
Granulocyte Colony-Stimulating Factor
18
Surgical Procedures, Operative
17
Sirolimus
17
Mesna
17
Melphalan
17
Dactinomycin
17
Biopsy
17
eribulin
16
Specimen Handling
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Sarcoma
×
Midazolam
×
Clear all
NCT03016819
2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3
Recruiting
325 enrolled